Morphic Holding Inc (OQ:MORF)

Business Focus: Biotechnology & Medical Research

Apr 23, 2024 05:24 pm ET
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders
Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ: MORF) on behalf of stockholders. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws....
Apr 16, 2024 11:20 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Apr 15, 2024 03:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Apr 11, 2024 03:30 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Apr 05, 2024 07:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Apr 04, 2024 03:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Apr 02, 2024 06:02 pm ET
Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.
MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Morphic (NASDAQ: MORF). The investigation results from inaccurate statements Morphic may have made regarding its business operations and prospects.
Apr 02, 2024 10:00 am ET
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQ: MORF). Investors who purchased Morphic securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/morf.
Mar 28, 2024 01:09 pm ET
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders
Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ: MORF) on behalf of stockholders. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. If...
Mar 26, 2024 07:57 pm ET
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQ: MORF). Investors who purchased Morphic securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/morf.
Mar 26, 2024 03:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Mar 22, 2024 03:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Mar 20, 2024 01:57 pm ET
MORF Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Morphic Holding, Inc.  (NASDAQ:MORF)
Abraham, Fruchter & Twersky, LLP (https://aftlaw.com/), a nationally recognized law firm that focuses on protecting investors’ rights, is investigating whether Morphic Holding, Inc. (NASDAQ:MORF), a biopharmaceutical company, violated U.S. federal...
Mar 20, 2024 03:30 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Mar 19, 2024 08:00 am ET
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief...
Mar 05, 2024 04:05 pm ET
Morphic to Participate in March Investor Conferences
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March....
Feb 22, 2024 07:00 am ET
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- -GARNET phase 2 trial of MORF-057 in Crohn’s disease (CD) expected to begin enrolling in the first half of 2024- -Ended 2023 with...
Jan 27, 2024 07:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ: MORF) for violations of the securities laws.
Jan 17, 2024 05:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Jan 11, 2024 10:00 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF) investors concerning the Company’s possible violations of federal securities laws.
Jan 11, 2024 05:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Jan 10, 2024 08:19 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ:
Jan 08, 2024 11:45 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Jan 04, 2024 02:29 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ:
Jan 03, 2024 04:05 pm ET
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., Chief Executive Officer of Morphic, has...
Dec 21, 2023 11:45 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Dec 19, 2023 01:29 pm ET
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders
Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ: MORF) on behalf of stockholders. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws....
Dec 18, 2023 05:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Dec 14, 2023 11:23 am ET
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders
Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ: MORF) on behalf of stockholders. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws....
Dec 14, 2023 04:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Dec 13, 2023 05:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Dec 11, 2023 05:30 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Dec 08, 2023 05:17 pm ET
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders
Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ: MORF) on behalf of stockholders. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws....
Dec 07, 2023 01:23 pm ET
MORF REMINDER: Robbins LLP is Investigating the Officers and Directors of Morphic Holdings, Inc.
Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ: MORF) to determine whether certain Morphic officers and directors violated securities laws and breached fiduciary duties to shareholders. Morphic is a...
Dec 04, 2023 05:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Dec 01, 2023 03:59 pm ET
Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors
Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ: MORF) to determine whether certain Morphic officers and directors violated securities laws and breached fiduciary duties to shareholders. Morphic is a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for t
Nov 27, 2023 06:52 pm ET
MORF SHAREHOLDERS: Investors of Morphic Holdings, Inc. Should Contact Robbins LLP for Information About Our Investigation
Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ: MORF) to determine whether certain Morphic officers and directors violated securities laws and breached fiduciary duties to shareholders. Morphic is a...
Nov 22, 2023 02:35 pm ET
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders
Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ: MORF) on behalf of stockholders. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws....
Nov 22, 2023 02:23 pm ET
Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors
Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ: MORF) to determine whether certain Morphic officers and directors violated securities laws and breached fiduciary duties to shareholders. Morphic is a biopharmaceutical company that discovers and develops oral small-molecule integrin therapeutics f
Nov 22, 2023 05:30 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Nov 21, 2023 04:11 pm ET
Morphic Holding, Inc. Investors Should Contact Robbins LLP for Information About Our Investigation of MORF
Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ: MORF) to determine whether certain Morphic officers and directors violated securities laws and breached fiduciary duties to shareholders. Morphic is a...
Nov 21, 2023 05:30 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Nov 13, 2023 04:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Nov 10, 2023 08:00 am ET
Morphic to Present at November Investor Conferences
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming...
Nov 09, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Nov 07, 2023 01:15 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Nov 06, 2023 04:24 pm ET
Morphic Corporation: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Morphic Holding, Inc. (NASDAQ: MORF) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors. Morphic investors that lost money on...
Nov 05, 2023 03:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 03, 2023 07:00 am ET
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter...
Nov 02, 2023 05:05 pm ET
Morphic Under Investigation: Shareholders Are Encouraged to Contact Johnson Fistel for Their Options
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose...
Nov 02, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 27, 2023 02:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 25, 2023 05:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
NEW YORK, Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Oct 24, 2023 05:15 pm ET
Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose...
Oct 22, 2023 07:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 21, 2023 12:21 pm ET
Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers, or others violated securities laws by misreprese
Oct 19, 2023 03:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Oct 19, 2023 05:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 18, 2023 12:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 17, 2023 06:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 17, 2023 04:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 16, 2023 04:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 14, 2023 11:19 am ET
Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers, or others violated securities laws by misreprese
Oct 13, 2023 07:51 pm ET
Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose...
Oct 13, 2023 11:40 am ET
MORF INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Cont
SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic Holding, Inc. (NASDAQ: MORF) focused on whether Morphic as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
Oct 12, 2023 09:35 pm ET
MORF INVESTIGATION: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Conta
Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic Holding, Inc. (NASDAQ: MORF) focused on whether Morphic as well as certain of its top executives made false and/or misleading...
Oct 11, 2023 10:15 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 11, 2023 03:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.  The...
Oct 10, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 09, 2023 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 09, 2023 08:00 am ET
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete...
Oct 08, 2023 11:15 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 08, 2023 04:05 pm ET
MORF INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information t
The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic Holding, Inc. (NASDAQ: MORF) focused on whether Morphic and certain of its top executives made false and/or...
Oct 07, 2023 07:15 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 06, 2023 12:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 05, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 05, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 04, 2023 04:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 03, 2023 04:15 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Oct 02, 2023 04:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Sep 29, 2023 05:51 pm ET
Investigation of Morphic Holding, Inc. (MORF) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQ: MORF) complied with federal securities laws. On September 22, 2023, the Company released abstract data from its EMERALD-1 Phase 2a trial for...
Sep 29, 2023 01:13 pm ET
MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to
Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic Holding, Inc. (NASDAQ: MORF) focused on whether Morphic and certain of its top executives made false and/or misleading statements and/or failed to disc
Sep 29, 2023 03:30 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Sep 28, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Sep 27, 2023 01:15 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Sep 26, 2023 04:10 pm ET
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Tipirneni is expected to return to his role as Chief Executive...
Sep 26, 2023 11:45 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Sep 25, 2023 12:00 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws.
Sep 24, 2023 03:30 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ: MORF) for violations of the securities laws.
Sep 22, 2023 05:30 pm ET
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen across key measures at week 12, mMCS response of 45.7%...
Aug 29, 2023 08:00 am ET
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Marc Schegerin, MD, COO & CFO, will participate in a fireside...
Aug 09, 2023 04:05 pm ET
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer,...
Aug 03, 2023 07:05 am ET
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the second quarter...
Jun 06, 2023 04:05 pm ET
Morphic to Present at the Jefferies Global Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies...
May 12, 2023 08:30 am ET
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in a Fireside Chat at...
May 11, 2023 08:00 am ET
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous findings and add new support to mechanistic understanding of the molecule’s...
May 05, 2023 10:30 am ET
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the closing of an underwritten public offering of 6,133,334 shares of...
May 03, 2023 12:13 am ET
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an underwritten public offering of 5,333,334 shares of...
May 02, 2023 04:02 pm ET
Morphic Therapeutic Announces Proposed Public Offering
Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering of its common stock. In...
Apr 25, 2023 07:00 am ET
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary an
MORF-057 generally well tolerated with no safety signal observed- -MORF-057 achieves saturation of α4β7 receptor and demonstrates changes in α4β7 lymphocyte subsets that are consistent with Phase 1 MORF-057 data - -Conference call and webcast...
Apr 25, 2023 06:59 am ET
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter...
Apr 24, 2023 04:01 pm ET
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss topline...
Mar 03, 2023 09:05 am ET
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused...
Feb 23, 2023 08:00 am ET
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2022....
Feb 14, 2023 08:00 am ET
Morphic to Present at SVB Leerink Global Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink...
Jan 05, 2023 09:09 am ET
Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer,...
Nov 22, 2022 08:00 am ET
Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the EMERALD-2 phase 2b study of MORF-057 in ulcerative...
Nov 09, 2022 08:00 am ET
Morphic Announces Participation in 2022 Jefferies London Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will participate in a...
Nov 02, 2022 08:00 am ET
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter of...
Oct 25, 2022 04:05 pm ET
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the presentation of data from a new MORF-057 phase 1 study at the...
Oct 24, 2022 08:00 am ET
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the completion of targeted enrollment of 30 patients ahead of...
Oct 10, 2022 08:00 am ET
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the presentation of new phase 1 data from MORF-057 phase 1 studies...
Sep 28, 2022 12:00 pm ET
Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today applauds Timothy A Springer, PhD for receipt of the 2022 Albert Lasker Basic...
Sep 21, 2022 07:00 am ET
Morphic Celebrates Foundational Integrin Research Published in Cell
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today recognized a pioneering publication in the journal Cell. This article...
Sep 01, 2022 08:00 am ET
Morphic Announces Participation in 2022 Wells Fargo Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside...
Aug 03, 2022 08:00 am ET
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the second quarter...
Jun 09, 2022 09:00 am ET
Morphic to Present at 2022 Jefferies Global Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Bruce Rogers, Ph.D., President of Morphic, will give a...
May 18, 2022 07:30 am ET
Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice President of...
May 17, 2022 08:00 am ET
Morphic Announces Participation in 2022 RBC Capital Markets Global Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside...
May 12, 2022 08:00 am ET
Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced two key executive appointments. Dr. Bruce Rogers has been named...
May 04, 2022 08:00 am ET
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter of...
Apr 06, 2022 08:00 am ET
Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced two key leadership appointments. Dr. Brihad Abhyankar has joined...
Mar 30, 2022 08:00 am ET
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D. will participate in panel...
Mar 25, 2022 08:00 am ET
Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis
Morphic Therapeutic (Nasdaq: MORF), today announced the initiation of MORF-057-201, the EMERALD-1 study. EMERALD-1 is a phase 2a trial of MORF-057 in patients with moderate to severe ulcerative colitis. MORF-057 is a potent and selective, oral...
Mar 04, 2022 09:05 am ET
Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic President and CEO Praveen Tipirneni, M.D. will participate...
Feb 24, 2022 07:30 am ET
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2021....
Feb 22, 2022 08:00 am ET
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the Digital Oral Presentation of new data at the 17th Congress of...
Jan 05, 2022 08:00 am ET
Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer,...
Nov 16, 2021 09:00 am ET
Morphic Announces Participation in Upcoming Investor Conferences
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation in the upcoming investor conferences: Dr. Bruce N....
Nov 15, 2021 09:05 am ET
Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the presentation of new data from its αvβ8 integrin inhibition program at...
Nov 04, 2021 04:05 pm ET
Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter of...
Oct 12, 2021 04:05 pm ET
Morphic to Participate in Jefferies IBD Therapeutics Summit
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to take part...
Sep 01, 2021 08:00 am ET
Morphic Therapeutic Announces Participation in September Investor Conferences
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences: Dr. Praveen...
Aug 23, 2021 04:01 pm ET
Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors....
Aug 04, 2021 07:00 am ET
Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the second quarter...
Jul 09, 2021 06:35 am ET
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced positive results from its full phase 1 clinical trial for...
Jul 02, 2021 09:00 am ET
Morphic Therapeutic to Host Analyst and Investor Call on July 9, 2021
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss results from...
May 28, 2021 08:00 am ET
Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO’21 Virtual Congress
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that new Phase 1 data for MORF-057 will be presented in an ePoster...
May 28, 2021 07:30 am ET
Morphic Therapeutic to Present at the Jefferies Virtual Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to...
Apr 29, 2021 08:00 am ET
Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter of...
Apr 28, 2021 04:01 pm ET
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its Board of Directors. Ms. Gray is an accomplished leader in healthcare finance and serves as a...
Apr 12, 2021 08:00 am ET
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the presentation of the first preclinical data from its αvβ8...
Mar 02, 2021 08:25 pm ET
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of...
Mar 01, 2021 04:01 pm ET
Morphic Therapeutic Announces Proposed Public Offering
Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering in which it intends to...
Mar 01, 2021 07:00 am ET
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced positive interim results from its Phase 1 clinical trial of...
Mar 01, 2021 06:55 am ET
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2020....
Feb 22, 2021 08:00 am ET
Morphic Therapeutic to Host Analyst and Investor Call on March 1, 2021
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the...
Feb 16, 2021 04:05 pm ET
Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive...
Jan 05, 2021 08:00 am ET
Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the expansion of its research and development collaboration with...
Dec 30, 2020 08:00 am ET
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare...
Dec 04, 2020 08:00 am ET
Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W. Edwards, to its Board of Directors. Dr. Edwards is a veteran leader in the drug development industry,...
Nov 17, 2020 09:05 am ET
Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to...
Nov 09, 2020 07:00 am ET
Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and third quarter 2020 financial results....
Oct 12, 2020 07:00 am ET
Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a poster presentation with new preclinical data on MORF-057 at the...
Sep 23, 2020 06:30 am ET
Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the first healthy volunteers have received MORF-057 in a...
Sep 21, 2020 04:45 pm ET
Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD...
Sep 03, 2020 04:30 pm ET
Morphic Announces Participation in Upcoming Investor Conferences
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences: Praveen...
Aug 25, 2020 06:30 am ET
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, and AbbVie (NYSE: ABBV) today announced that AbbVie has exercised a license option...
Aug 10, 2020 07:00 am ET
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and second quarter 2020 financial results....
Jun 29, 2020 07:30 am ET
Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a presentation highlighting Morphic’s product candidate MORF-057...
Jun 18, 2020 08:00 am ET
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief...
May 27, 2020 08:00 am ET
Morphic to Present at the Jefferies Virtual Healthcare Conference
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a...
May 06, 2020 04:05 pm ET
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and first quarter 2020 financial results....
Apr 29, 2020 04:15 pm ET
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a...
Apr 07, 2020 08:00 am ET
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financial...
Mar 17, 2020 08:00 am ET
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Peter G. Linde, M.D., as chief medical officer....
Feb 28, 2020 08:00 am ET
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief...
Feb 27, 2020 04:05 pm ET
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2019....
Feb 14, 2020 11:29 am ET
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced an oral presentation today highlighting Morphic’s product candidate...
Jan 08, 2020 12:00 pm ET
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive...
Nov 18, 2019 04:15 pm ET
Morphic to Present at the Jefferies 2019 London Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive...
Nov 12, 2019 04:24 pm ET
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter...
Aug 30, 2019 01:00 pm ET
Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive...
Aug 12, 2019 06:30 am ET
Morphic Announces Corporate Highlights and Second Quarter 2019 Financial Results
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the second quarter...
Jul 01, 2019 04:30 pm ET
Morphic Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its initial public offering of 6,900,000 shares of its common stock at a price to the public of $15.00 per share, which includes 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. The shares began trading on The Nasdaq Global Market on June 27, 2019 under the symbol “MORF.” Morphic received gross proceeds, before deducting underwriting discounts and commissions an
Jun 26, 2019 08:30 pm ET
Morphic Announces Pricing of Upsized Initial Public Offering
Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $15.00 per share. The shares are expected to begin trading on The Nasdaq Global Market on June 27, 2019 under the symbol “MORF.” The offering is expected to close on July 1, 2019, subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.